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Abstract
Background: Influenza A virus mutates rapidly, rendering antiviral therapies and vaccines directed against virus-
encoded targets ineffective. Knowledge of the host factors and molecular pathways exploited by influenza virus
will provide further targets for novel antiviral strategies. However, the critical host factors involved in influenza virus
infection have not been fully defined.
Results: We demonstrated that LAMP3, a member of lysosome-associated membrane glycoprotein (LAMP) family,
was significantly induced in human lung epithelial (A549) cells upon influenza A virus infection. Knockdown of
LAMP3 expression by RNA interference attenuated production of viral nucleoprotein (NP) as well as virus titers.
Confocal microscopy results demonstrated that viral NP is colocalized within LAMP3 positive vesicles at early stages
of virus infection. Furthermore, knockdown of LAMP3 expression led to a reduction in nuclear accumulation of viral
NP and impeded virus replication.
Conclusions: LAMP3 is an influenza A virus inducible gene, and plays an important role in viral post-entry steps.
Our observations may provide insights into the mechanism of influenza virus replication and potential targets for
novel anti-influenza therapeutics.
Background
Influenza viruses are a significant cause of morbidity
and mortality in human as well as avian and animal spe-
cies worldwide. Antiviral drugs targeting influenza viral
proteins, such as oseltamivir, zanamivir, amantadine and
rimantadine, have been licensed for treatment of influ-
enza [1]. However, as influenza virus undergoes muta-
tion very rapidly and can evolve drug resistance, the
antiviral drugs can become ineffective during a flu out-
break [2,3]. Recently, host factors exploited by influenza
virus have attracted increasing interest because thera-
peutics targeting these cellular factors may inhibit viral
replication independent of the antigenic properties of
the virus. Therefore, identification of host factors
required for viral replication and development of anti-
viral agents targeting host factors is a promising strategy
for reducing the viral resistance [4-6]. Recently, several
research groups have identified a variety of host cell fac-
tors that are important for influenza virus replication by
using genome-wide RNA interference screenings in con-
junction with other integrative genomics strategies
[7-11]. These findings provide a global view of the cellu-
lar processes that are exploited by influenza viruses and
highlighted potential targets which may be used in anti-
viral research.
The influenza A virus genome is composed of eight
segments of negative-sense, single-stranded RNA, which
encodes 11 proteins [10]. Hemagglutinin (HA) and
neuraminidase (NA) are critical for viral entry and
release, respectively, and viral polymerase, composed of
three subunits, PA, PB1, and PB2, is responsible for
replication and transcription. Following initial interac-
tion of its HA with its N-acetylneuraminic (sialic) acid
receptor on the cell surface, the virus enters the cell by
receptor-mediated endocytosis. Upon endosomal acidifi-
cation, the HA protein undergoes conformational
changes and mediates fusion between the viral envelope
and endosomal membrane. The acidic environment of
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core and the release of the viral ribonucleoprotein
(vRNP) into the cytoplasm [12]. The vRNPs are then
rapidly imported into the nucleus to catalyze viral gen-
ome replication and RNA transcription [13]. Subse-
quently, newly formed vRNPs, in association with other
viral proteins are exported into the cytoplasm and trans-
ported to the cell membrane for budding and release.
Transcriptional profiling reveals that a variety of host
factors were induced upon influenza virus infection [14].
These viral inducible factors may play essential or inhi-
bitory roles in the viral lifecycles, such as viral entry,
vRNP trafficking, transcription, viral assembly and bud-
ding [9]. However, the function and regulatory mechan-
isms of these host factors remains largely unknown.
We here report that a host factor, lysosome-associated
membrane glycoprotein 3 (LAMP3) is involved in the
post-entry stages of influenza A virus infection. We
found that LAMP3 was significantly up-regulated upon
influenza A virus infection. Knockdown of LAMP3
expression by RNA interference inhibits viral replication
in the early stage, suggesting that LAMP3 may play an
important role in influenza life cycles.
Results
LAMP3 is induced upon influenza A virus infection
Influenza A virus infection induces multiple host gene
expression. Interestingly, many of the up-regulated host
factors appear to function by facilitating virus replication
[9]. To investigate the dynamic host gene response pro-
file upon influenza A virus infection, we utilized DNA
microarray technology to determine global cellular
mRNA levels at different time points post viral infection.
Briefly, A549 cells were infected with influenza A/PR/8/
34 virus at a multiplicity of infection (MOI) of 0.5.
Then, total RNA were prepared at 4 h, 12 h, 24 h, and
48 h post-infection (p.i.), and were subjected to global
gene expression analysis by microarray chips (Capitalbio
h u m a ng e n o m eo l i g oa r r a ys e r v i c e ,d a t an o ts h o w n ) .
Notably, LAMP3, also known as DC-LAMP, TSC403 or
CD208 [15], was found to be among the most signifi-
cantly upregulated genes. Upon A/PR/8/34 virus infec-
tion, LAMP3 mRNAs were stimulated a 45.2 fold at 24
h p.i., and a 34.7 fold at 48 h p.i., respectively (Figure
1A). Nevertheless, the mRNA levels of two other LAMP
protein family members, LAMP1 and LAMP2, were not
altered at any time points indicated, suggesting that
LAMP3 may be specifically stimulated by viral infection.
To confirm the gene chip data, we used RT-PCR to
detect the mRNA level of LAMP1, LAMP2, and LAMP3
at different time points post influenza A virus infection.
Consistently, LAMP3, but not LAMP1 and LAMP2, is
significantly induced upon influenza A virus infection
(Figure 1B). Finally, we determined the protein expres-
sion level of LAMP3 in A549 cells and IFN-deficient
Vero cells [16], and the results demonstrated that, upon
Figure 1 LAMP3 is specifically induced upon influenza A virus infection. (A) Microarray results for LAMP1, LAMP2, and LAMP3 expression at
different time points post influenza virus infection. A549 cells were infected with A/PR/8/34 virus at a MOI of 0.5. At indicated time points post-
infection (p.i.), total cellular RNA was extracted and subjected to microarray analysis. (B) RT-PCR analysis for LAMP1, LAMP2, and LAMP3
expression. A549 cells were infected with A/PR/8/34 virus. After 12 h, 18, or 24 h, total cellular RNA was extracted and subjected to RT-PCR with
specific primers. GAPDH gene was used as an internal control. (C) Western blot analysis for LAMP3 expression. A549 or Vero cells were treated as
indicated in (B) and were lysed with RIPA buffer. Cell lysates were subjected to Western blot analysis with antibodies against LAMP3. b-actin was
used as a loading control.
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cells but not in Vero cells, indicating that LAMP3
induction may be interferon-dependent (Figure 1C).
Knockdown of LAMP3 inhibits influenza A virus
replication
LAMP3 is significantly and specifically induced upon
influenza A virus infection, implying that LAMP3 may
be involved in virus replication. To address the role of
LAMP3 in virus replication, we silenced the expression
of LAMP3 or LAMP1 in A549 cells by using specific
siRNA oligonucleotides. Total amount of the LAMP3 or
LAMP1 protein was detected at 72 h post transfection
by Western blot analysis. In cells transfected with
LAMP3 or LAMP1 siRNA, protein expression was sub-
stantially inhibited (Figure 2A). We next examined if
loss of LAMP3 or LAMP1 affects viral protein synthesis.
A549 cells were infected withA/PR/8/34 virus at a MOI
of 1 or 0.5 after transfection with either scrambled (con-
trol) or gene specific siRNA for 72 h. Twenty four hours
post viral infection, cells were fixed and stained with
anti-NP and anti-lamin A antibody simultaneously for
in-cell western analysis [17]. The results showed that
the amount of NP production in LAMP3 knockdown
cells is remarkably lower than that in control cells and
in LAMP1 knockdown cells (Figure 2B), indicating that
loss of LAMP3, but not LAMP1, affects virus protein
synthesis. Further quantitative analysis for in-cell wes-
tern results showed that NP production is reduced by
nearly 50% in the LAMP3 knockdown cells (Figure 2C).
Then, we determined if knockdown of LAMP3 reduces
virus titers. Briefly, A549 cells were transfected with
Figure 2 Knockdown of LAMP3 inhibits influenza A virus replication. (A) Knockdown of LAMP1 or LAMP3 by RNAi. A549 cells were
transfected with the siRNA against LAMP1, LAMP3 or a non-targeting control RNA (scrambled) (50 nM). Seventy two hours later, cells were lysed
and subjected to Western blot analysis using antibody against LAMP1 or LAMP3. (B) In-cell western assay for NP production. A549 cells grown in
96-well plates were transfected siRNAs as indicated in (A). After 72 h, cells were either infected or mock infected by influenza virus, and were
subjected to in-cell western assay at 24 h p.i.. NP was visualized via labeling with NP specific antibody, and endogenous lamin A was labeled as
a control. (C) Quantitative analysis of in-cell western using Odyssey Imaging System. * Student’s t test, p = 0.031.(D) A549 cells were transfected
with LAMP3, LAMP1 or control siRNAs, cells were then infected with A/PR/8/34 virus at a MOI of 0.1 at 72 h post-transfection. Cell supernatants
were harvested and subjected to TCID50 assay 24 h p. i.(E) A549 cells were left untransfected, or were transfected with an IFN-b reporter plasmid,
along with the scrambled siRNA, siRNA against LAMP3 (SiLAMP3), or poly (I:C) at 50 ng/ml (a positive control for IFN promoter activation), and
analyzed 48 h later for luciferase assay.
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infected with A/PR/8/34 virus at a MOI of 0.1 after 72
h. At 24 h p.i., viral supernatants were harvested and
subjected to TCID50 assay. Consistently, the virus titer
was reduced by a 1.5 log10 in LAMP3 knockdown cells
compared to the control cells or the LAMP1 knock-
down cells (Figure 2D), indicating that LAMP3 plays an
important role in the viral replication. Since some siR-
NAs could induce interferon response, we tested if the
inhibition of viral replication by LAMP3 siRNA is
related to siRNA induced interferons. The results sug-
gested that transfection of LAMP3 or scrambled siRNAs
could not induce IFN-b promoter activity (Figure 2E),
indicating that inhibition of viral replication could be
attributed to LAMP3 depletion rather than siRNA
induced IFN response.
Influenza virus accumulates in LAMP3 positive vesicles
Previous studies suggested that LAMP3 is involved in
the endosomal/lysosomal pathways [18]. To examine if
LAMP3 is involved in influenza A virus trafficking, we
determined the localization of LAMP3 and the virus NP
by confocal microscopy. First we detected if LAMP3 is
localized to the endosome compartments. Hela cells
were transfected with GFP tagged LAMP3 and then
labeled with EEA1, a marker of early endosomes [19].
Upon merging both channels, the LAMP3-GFP largely
colocalize with the EEA1 labeled cytoplasmic compart-
ments of early endosomes (Figure 3A), indicating that
LAMP3 may reside in the early endosomes, which is
involved in the influenza endocytic pathway. We next
determined if the localization of LAMP3 changes upon
virus infection. Hela cells transfected with LAMP3-GFP
were infected with A/PR/8/34 virus at a MOI of 10.
After 1 h, cells were fixed and subjected to confocal
microscopy analysis. In the virus infected cells, part of
the LAMP3 translocated from the cytoplasm to the
plasma membrane (Figure 3B), suggesting that virus
infection may regulate LAMP3 trafficking. Finally, we
examined if LAMP3 is colocalized with influenza virus.
LAMP3-GFP transfected cells were infected with A/PR/
8/34 virus at a MOI of 10 for 1 h and stained with anti-
body against NP. By confocal microscopy, the cytoplas-
mic speckles of influenza NP colocalized within the
LAMP3 positive vesicles (Figure 3C), indicating that
LAMP3 may be involved in influenza endocytosis or
vRNP trafficking pathways.
LAMP3 regulates post-entry steps of influenza A virus
replication
To evaluate which steps of viral life cycles LAMP3 may
be involved in, we monitored the localization of the NP
during influenza A virus infection. A549 cells were
transfected with a LAMP3 specific siRNA or a control
s i R N A ,a n dt h e ni n f e c t e dw i t hA / P R / 8 / 3 4v i r u sa ta
MOI of 10. Cells were fixed at 1.5 h, 4 h, and 8 h, and
then subjected to indirect immunofluorescence assays
for detection of NP localization. As indicated in the Fig-
ure 4A, at 1.5 h p.i., viral NP were observed internalized
in the cytoplasm in both control and LAMP3 knock-
down cells, suggesting that depleting LAMP3 may not
inhibit virus entry. Intriguingly, at 4 h p.i., about 70% of
NP translocated to the cell nuclei in the control cells;
whereas in the LAMP3 knockdown cells, NP largely
remained in the cytoplasm (Figure 4A and 4B). At 8 h
p.i., the NP protein diffused in the control cells but
accumulated as cytoplasmic puncta in the LAMP3
depleted cells, suggesting a role of LAMP3 in post-entry
steps of influenza virus infection, such as viral uncoating
or viral ribonucleoproteins (vRNP) trafficking. Consis-
tent with the in-cell western results, at a MOI of 0.1,
the production of NP is substantially decreased in the
LAMP3 knockdown cells compared to the control cells
(Figure 4A), confirming the role of LAMP3 in virus
replication.
Discussion
Influenza viruses have the ability to exploit or impede
host cellular responses to support viral replication, and
the interactions between viral and cellular factors deter-
mine host susceptibility to influenza infection [14,20].
Novel influenza A virus strains emerge periodically,
resulting in global pandemics. Thus, identification of cri-
tical host factors for influenza virus replication will pro-
vide insights into the development of future anti-flu or
broad-spectrum antiviral approaches.
LAMP family proteins have been implicated in the
regulation of multiple cellular processes, such as cell
growth, adhesion, and metastasis. Both LAMP1 and
LAMP2 are located primarily in lysosomes, and shuttle
between lysosomes, endosomes, and the plasma mem-
brane [21-27]. LAMP3 was first cloned as a novel
human lung-specific gene, and was subsequently found
to be overexpressed in malignant cells [28,29]. Recent
publications suggest that LAMP3 have metastatic poten-
tial in cancers [15]. However, the role of LAMP3 in
virus-host interactions has not yet been clarified. Here
we showed that the expression of LAMP3 is up-regu-
lated upon influenza virus infection. Further we demon-
strated that knockdown of LAMP3 inhibited nuclear
accumulation of influenza NP protein at early stages of
viral infection. These data indicated a critical role for
LAMP3 in influenza virus replication.
LAMP3 bears significant similarity to LAMP1 and
LAMP2 [28], and may promote metastasis in the same
way as LAMP1 and LAMP2 [15]. Intriguingly, only
LAMP3 was significantly up-regulated during influenza
virus infection. It is not clear whether the expression of
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Page 4 of 8Figure 3 Influenza virus accumulates in LAMP3 positive vesicles. (A) Localization of LAMP3 and early endosome marker EEA1. Hela cells
were transfected with a LAMP3-GFP plasmid. Eighteen hours later, cells were stained with EEA1 antibody and analyzed by confocal microscopy.
(B) LAMP3 translocated to plasma membrane during influenza virus infection. Hela cells transfected with LAMP3-GFP were infected with A/PR/8/
34 virus at a MOI of 10 for 1 h. Cells were then fixed and analyzed by confocal microscopy. (C) LAMP3 colocolized with influenza A virus. Hela
cells were transfected with LAMP3-GFP for 18 h and then infected with influenza A virus at 10 MOI. After 1 h, cells were stained with the anti-NP
antibody and were subjected to confocal microscopy analysis.
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virus-induced interferon. Our results indicated that
influenza A virus could not induce LAMP3 expression
in the IFN-deficient Vero cells. Meanwhile, microarray
data mining suggested that LAMP3 was significantly
upregulated in interferon treated human blood mono-
cytes [30]; implicating a mechanism by which LAMP3
expression may be regulated by virus-induced interferon.
Our results demonstrated that knockdown of LAMP3
did not affect virus entry while attenuated nuclear accu-
mulation of NP at 4 h post-infection. These results sug-
gest that LAMP3 may play a role in influenza virus
post-entry events, such as virus uncoating, cytosolic
transport, or nuclear import of viral components. Con-
focal microscopy analysis suggested that LAMP3 is loca-
lized to endosomal compartment, and virus particles are
found to be accumulated in the LAMP3 positive vesi-
cles, suggesting that it is more likely that LAMP3 plays
ar o l ei ne a r l yp o s t - e n t r ys t a g e so fi n f l u e n z ai n f e c t i o n
rather than nuclear trafficking of vRNP. Further bio-
chemical experiments, such as investigating vRNP-
LAMP3 interaction by immunoprecipitation, will pro-
vide insights into the mechanism by which LAMP3 reg-
ulates influenza virus infection and replication.
In conclusion, we have identified LAMP3 as a specific
host factor that is involved in influenza virus infection
at post-entry stages. Further investigations of the roles
for LAMP3 in influenza virus infection will provide
insight into the network of host-virus interactions that
control the early steps of influenza virus replication and
new pharmacological targets for anti-viral therapies.
Methods
Cell culture and virus infection
The human lung carcinoma cell line A549, human cer-
vical cancer cell line HeLa, Madin Darby Canine kidney
cell line MDCK and African green monkey kidney cell
line Vero were purchased from American Type Culture
Collection (ATCC; Manassas, VA) and were maintained
in the Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum (FBS; HyClone, Logan, UT), 100 U/ml
penicillin, and 100 μg/ml streptomycin at 37°C. A influ-
enza A virus strain A/PR/8/34 (H1N1) was used in this
study. For virus infection, A549 cells or MDCK cells
were inoculated with virus at the indicated multiplicities
of infection (MOI). Two hours later, the inoculum was
removed, and cells were washed twice with Hank’s solu-
tion prior to the addition of serum-free DMEM contain-
ing 5% BSA and 1 μg/ml TPCK-trypsin (Sigma-Aldrich,
St. Louis, MO)[16].
Reverse transcription PCR
To determine the mRNA expression level of various
LAMPs during influenza A virus infection, cells were
infected with A/PR/8/34 virus at a MOI of 0.5. At dif-
ferent time points post infection, total cellular RNA was
extracted using Trizol reagent (Invitrogen) according to
the manufacturer’s instructions. RNA samples were trea-
ted with DNase I (Pierce, Rockford, IL), and reversely
transcribed using a Superscript cDNA synthesis kit
(Invitrogen) following the manufacturer’sp r o t o c o l s .
cDNA samples were subjected to PCR amplification and
Figure 4 LAMP3 regulates post-entry steps of influenza A virus replication. (A) NP localization during influenza A virus replication. A549
cells were transfected with a LAMP3 specific siRNA or a control siRNA (Scrambled), and then infected with A/PR/8/34 virus at a MOI of 10 or 0.1.
Cells were fixed at indicated time points respectively, and then subjected to indirect immunofluorescence assays for NP localization. (B)
Quantitative analysis for ratios of NP nuclear imported cells/total infected cells. Analyses were carried out for cells infected with A/PR/8/34 virus
at a MOI of 10 for 4 h. * Student’s t test, p = 0.016.
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follows:
LAMP1, 5’-GCGAGCTCCAAAGAAATCAA-3’ (for-
ward), 5’-TGGACCTGGGTGCCACTAA-3’ (reverse),
LAMP2, 5’-CTCTGCGGGGTCATGGTG-3’ (forward),
5’-CGCACAGCTCCCAGGACT-3’ (reverse) LAMP3, 5’-
GCGTCCCTGGCCGTAATT-3’ (forward) 5’-
TGCTTAGCTGGTTGCTGGA-3’ (reverse).
Western blot analysis
Cells were lysed in RIPA buffer containing 150 mM
NaCl, 25 mM Tris (pH 7.4), 1% NP-40, 0.25% sodium
deoxycholate, 1 mM EGTA, and 1 mM EDTA with pro-
teinase inhibitor cocktail (Roche, Indianapolis, IN), and
total protein concentration was determined by the BCA
Protein Assay Reagent Kit (Pierce, Rockford, IL)before
separation by SDS-PAGE. Expression of LAMP1 or
LAMP3 protein was detected by the rabbit polyclonal
anti-LAMP1 antibody (Sigma, L1418) or the rabbit poly-
clonal anti-LAMP3 antibody (AVIVA, ARP41598_P050),
respectively.
RNA interference
siRNA against LAMP1 (M-013481-01), LAMP3 (M-
004716-01), along with the non-targeting control (D-
001206-13-05) were purchased from Dharmacon
(Boulder, CO). A549 cells were transfected with the siR-
NAs (50 nM) using Dharmafect1 (Dharmacon) accord-
ing to the manufacturer’s instructions.
Repoter assays
A549 cells were seeded in 24-well plates at a cell density
of 1.5 × 10
5 cells per well. The next day, cells were left
untransfected, or were transfected with pGL3-IFN-b-Luc
and pRL-SV40, along with the scrambled siRNA, siRNA
against LAMP3, or poly (I:C) using Lipofectamine 2000
(Invitrogen). At 48 h post transfection, cells were har-
vested, and cell lysates were subjected to luciferase
activity assays (Promega, Madison, WI).
Indirect immunofluorescence assay
A549 cells either infected or mock infected by influenza
A virus were fixed in 4% paraformaldehyde and permea-
bilized with PBS containing 0.5% Triton X-100 (pH 7.4).
Then, the cells were blocked with PBST (PBS containing
0.1% Tween-20; pH 7.4) containing 5% BSA for 50 min
at room temperature. Further, the cells were incubated
with mouse polyclonal anti-influenza A virus NP anti-
body (1:500; Millipore, Temecula, CA) at 4°C overnight.
After three washes with PBST, cells were incubated with
anti-mouse IgG/DyLight594-conjugated antibody (1:500;
Zhongshanjinqiao Biotech, Beijing, China) for 1 h, and
cell nuclei were labeled with Hoechst dye 33258 (Beyo-
time, Nantong, China) according to the manufacturer’s
instructions. For localizing LAMP3 and influenza virus,
Hela cells were transfected with LAMP3-GFP (Origene,
Rockville, MD), and were stained with NP antibody 18 h
post-transfection. After extensive washes with PBST,
cells were incubated with anti-mouse IgG/DyLight594-
conjugated antibody as indicated above. Fluorescence
images were obtained by using a Leica TCS SP5 laser
scanning confocal microscope.
In-cell western assay
The cells infected with influenza A virus or mock
infected were immunostained with influenza A virus NP
antibody together with a rabbit IgG antibody against
Lamin A (1:1000; Sigma-Aldrich) as described above.
Subsequently, the cells were washed and stained with
goat anti-mouse IgG IRDye 800 antibody (1:500; LI-COR,
Lincoln, NE) and goat anti-rabbit IgG IRDye 680 anti-
body (1:500; LI-COR). Protein expression was quantified
using the Odyssey Imaging System. For statistical analy-
sis, integrated intensities of fluorescence in wells were
determined using software provided with the imager sta-
tion (LI-COR). The relative amount of NP protein was
obtained by normalizing to the endogenous lamin A.
TCID50 assay
The TCID50 assay was performed in MDCK cells
according to the protocol recommended by the World
Health Organization (http://www.who.int/csr/resources/
publications/influenza/whocdscsrncs20025rev.pdf), and
data were analyzed according to the Reed and Muench
method [31].
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